{"pub": "cnbc", "title": "Top biotech investor says Trump's criticism of Pfizer is scaring drug companies from raising prices", "url": "https://cnbc.com/2018/07/23/carl-icahn-protege-denner-says-trumps-criticism-of-pfizer-is-scaring-.html", "language": "en", "published_at": "2018-07-23", "downloaded_at": "2019-09-02 07:09:30.032002+00:00", "text": "Sarissa Capital Management chief investment officer Alex Denner believes President Donald Trump\u2019s criticism of pharmaceutical giant Pfizer is having an impact on how other companies in health care set their prices.\n\n\u201cBy putting pressure on one particular company, I think all the companies are saying: We don\u2019t want to be Pfizer,\u201d Denner said in an exclusive video for CNBC PRO. \u201cEven if they maybe raise prices in a different way \u2013 if they typically raise prices in a different way or do it on a different subset of products, they\u2019re going to be thinking twice.\u201d\n\nThe investor\u2019s comments came less than 10 days after Trump bashed Pfizer and other drugmakers for raising the price of 104 different drugs, arguing that such companies . For its part, Pfizer raised the price of 41 drugs by as much as 9 percent, though it also lowered prices on five drugs by as much as 44 percent.\n\nIn a statement, Pfizer defended itself and argued that the price adjustments only affected a minor portion of the company\u2019s extensive portfolio of treatments. The company's stock fell 0.2 percent Monday, but is up 2.9 percent since January; is up 5 percent year to date.\n\n\"Our portfolio includes more than 400 medicines and vaccines; we are modifying prices for approximately 10 percent of these, including some instances where we\u2019re decreasing the price,\" Pfizer said in a statement. \"Importantly, list prices do not reflect what most patients or insurance companies pay.\u201d\n\nDenner, a Carl Icahn protege, is known for his shareholder activism in the biotechnology and pharmaceutical industries. Through Sarissa, he currently has active stakes in Biogen, Ironwood Pharmaceuticals and The Medicines Company.\n\nSarissa oversees $535 million in assets under management according to its latest Form ADV filing.\n\nClick here to see the full video, but you must be a CNBC Pro subscriber.", "description": "Sarissa's Alex Denner says President Trump\u2019s criticism of pharmaceutical giant Pfizer is having an impact on how other companies in health care set their prices.", "authors": ["Thomas Franck"], "top_image": "https://image.cnbcfm.com/api/v1/image/105338315-1531942040013denner2.jpg?v=1531942108"}